Bone Fragility with Contractures, Arterial Rupture, and Deafness (BCARD)

Bone fragility with contractures, arterial rupture, and deafness (BCARD) is a rare, inherited connective-tissue disorder. The body’s collagen—the protein that gives strength to bone, blood vessels, skin, eyes, and the inner ear—does not mature correctly. Because collagen is weak, bones are fragile, some joints are stuck in a bent position (contractures), arteries can form aneurysms and may tear, and hearing loss can develop. The problem usually starts before birth or in early life, and it involves many organs at once. Scientists have shown that most people with this condition have harmful changes in a gene called PLOD3, which makes an enzyme named lysyl hydroxylase-3 (LH3). LH3 helps modify collagen; when it does not work, collagen is weak. PMC+3NCBI+3NCBI+3

BCARD syndrome is a very rare inherited connective-tissue disorder where bones break easily, joints are stiff or fixed at birth (contractures), large arteries can tear or dissect, and hearing is reduced or lost. Reports link the syndrome to loss of activity of lysyl-hydroxylase 3 (LH3; gene PLOD3)—an enzyme that helps collagen form strong, stable cross-links. When LH3 is deficient, collagen in bone, vessels, and the inner ear is weaker. Clinically, people can have low bone density, scoliosis, finger and large-joint contractures, prominent knees, episodic pathologic fractures, arterial aneurysm/rupture risk, and sensorineural deafness; eye problems (high myopia, cataract, retinal detachment risk) are also described. Because it is so rare, most guidance comes from case descriptions and from related conditions (osteogenesis imperfecta, arthrogryposis, and vascular Ehlers-Danlos), plus general best practices in bone health, vascular protection, and hearing care. NCBI+2National Organization for Rare Disorders+2

BCARD crosses three care worlds—(1) bone fragility like osteogenesis imperfecta (OI), (2) congenital contractures like arthrogryposis multiplex congenita (AMC), and (3) arterial fragility like vascular Ehlers-Danlos syndrome (vEDS). So, multidisciplinary care (genetics, orthopedics, physiatry/physiotherapy, cardiology/vascular surgery, audiology/ENT, ophthalmology) and personalized risk planning are essential. NCBI+3NCBI+3PMC+3

Other names

Doctors and genetics sites also use these names for the same disease:

• BCARD syndrome (an acronym of the main features). NCBI

• Connective tissue disorder due to lysyl hydroxylase-3 (LH3) deficiency. MalaCards

• Bone fragility–contractures–arterial rupture–deafness syndrome. MalaCards

Types

There are no formal subtypes agreed upon yet. Instead, experts describe a spectrum: some children show severe signs before birth (many fractures, clubfoot, vessel problems), while others have milder bone and hearing findings and develop vascular risks later. The range likely reflects which PLOD3 variants are present and how they impair the multiple activities of the LH3 enzyme (hydroxylation and two glycosylation steps). PMC+2Wiley Online Library+2

---

Causes

BCARD is genetic. The root cause is defective collagen processing from PLOD3 variants. Below are 20 clear, evidence-based causes and contributors, explained in everyday terms:

1. Biallelic PLOD3 variants (autosomal recessive). A child inherits one faulty gene copy from each parent. This is the main cause. NCBI+1

2. Loss-of-function mutations. Some DNA changes stop LH3 being made or working at all. PMC

3. Missense mutations in the LH activity site. A small change in one amino acid can block lysine hydroxylation in collagen. PMC

4. Missense mutations in the collagen glycosylation sites. LH3 also adds sugars to collagen; errors here weaken tissues. PMC

5. Splice-site mutations. Faulty cutting of the gene message produces a broken protein. MalaCards

6. Frameshift or nonsense mutations. These introduce early stop signals, producing a short, nonfunctional enzyme. PMC

7. Compound heterozygosity. Two different harmful variants (one on each allele) combine to cause disease. PMC

8. Homozygosity (often with parental relatedness). Two identical harmful variants can cause a severe form. Genetic Diseases Info Center

9. Protein instability and degradation. Some variants make LH3 unstable so cells destroy it. PMC

10. Defective collagen IV and VI maturation. Basement membranes and muscle/skin matrices become weak, affecting vessels, skin, and bone. PMC

11. Abnormal collagen cross-linking in bone. Poor cross-links reduce bone mineral quality, leading to osteopenia and fractures. Genome Database

12. Basement-membrane fragility in vessels. This raises the risk of aneurysm and arterial rupture. NCBI

13. Inner-ear connective-tissue weakness. This contributes to sensorineural hearing loss. NCBI

14. Skin and fascia weakness. Blistering, easy bruising, and soft skin occur when collagen fails. MalaCards

15. Ocular connective-tissue fragility. High myopia, cataract, and retinal problems reflect weak ocular collagen. NCBI

16. Diaphragm and visceral tissue fragility. Thin tissue can tear under normal stress. MalaCards

17. Growth disturbance. Weak collagen in growth plates can stunt growth and shape the skeleton. MalaCards

18. Scoliosis from soft bones and ligaments. Unstable spines curve over time. PMC

19. Possible modifying genes in collagen pathways. Researchers suspect other collagen-processing genes may modify severity. (Emerging evidence.) Wiley Online Library

20. Acquired stressors that increase risk (modifiers, not root causes). High blood pressure and physical strain may precipitate vascular events in fragile arteries. (General vascular-risk logic applied to a known fragile vessel wall.) NCBI

---

Symptoms

Each person is different, but these are common, plain-language features:

1. Fragile bones with fractures after minor bumps or twists. NCBI

2. Low bone density (osteopenia/osteoporosis) in childhood. NCBI

3. Joint contractures (fingers, elbows, knees, feet) present at birth or early life. NCBI

4. Clubfoot and prominent knees from altered limb shape. MalaCards

5. Spinal curvature (scoliosis). PMC

6. Short stature or slow growth. MalaCards

7. Sensorineural hearing loss that may begin in childhood or adolescence. NCBI

8. Arterial aneurysm or tearing, sometimes in the brain or limbs, which is life-threatening. NCBI

9. Eye problems such as high myopia, cataract, and risk of retinal detachment. NCBI

10. Skin fragility, easy bruising, blistering, and reduced palmar creases. MalaCards

11. Soft, easily damaged nails and abnormal hair. MalaCards

12. Facial differences (for example, widely spaced eyes) reported in some patients. MalaCards

13. Muscle and tendon tightness around joints due to long-standing contractures. NCBI

14. Breathing issues if there is chest wall deformity or diaphragmatic fragility. MalaCards

15. Developmental delays in some children, often secondary to medical complications or sensory loss. MalaCards

---

Diagnostic tests

Doctors combine bedside examination, functional tests, labs, and imaging. Here are 20 specific tests and why each helps:

Physical examination 

1. General musculoskeletal exam. The doctor looks for fractures, bowed limbs, blue sclerae, posture, and gait. This maps bone fragility and deformity. NCBI

2. Joint contracture assessment. Careful range-of-motion testing identifies fixed bends and guides therapy plans. NCBI

3. Skin and soft-tissue exam. Easy bruising, blistering, scars, and soft skin suggest a collagen disorder. MalaCards

4. Eye exam (including slit-lamp where available). Detects myopia, cataract, and retinal risk early. NCBI

Manual/functional tests 

1. Pure-tone audiometry. Measures the degree and type of hearing loss. Nature
2. Tympanometry. Checks eardrum and middle-ear function to separate conductive from sensorineural causes. Nature
3. Bedside tuning-fork tests (Weber/Rinne). Simple clinic tests that quickly screen for hearing patterns. ScienceDirect
4. Goniometry of joints. Measures contracture angles so progress can be tracked over time. NCBI

Laboratory and pathological tests 

1. Genetic testing of the PLOD3 gene (sequencing). Confirms the diagnosis and guides family counseling. Prenatal testing is possible in at-risk pregnancies. MalaCards
2. Collagen studies in cultured fibroblasts (specialized labs). Show abnormal collagen modification and secretion. PMC
3. Skin biopsy with electron microscopy (selected cases). Reveals basement-membrane and fibril abnormalities typical of collagen disorders. ResearchGate
4. Bone turnover markers (context-dependent). Help screen for high bone remodeling in children with many fractures. (Adjunctive.) Genome Database
5. Routine labs before surgery or anesthesia. Basic safety tests; not diagnostic but essential in multisystem disease. (Clinical consensus practice.)

Electrodiagnostic/auditory physiology 

1. Auditory brainstem response (ABR). Objective test of the hearing nerve and brainstem pathway; useful in infants. Nature
2. Otoacoustic emissions (OAE). Screens outer hair-cell function in the cochlea. Nature
3. Electrocochleography (ECochG) (selected centers). Measures inner-ear potentials when the history suggests inner-ear dysfunction. Nature

Imaging 

1. Skeletal survey X-rays. Detects fractures, bone deformities, and vertebral changes. NCBI
2. DXA scan (bone density). Quantifies osteopenia/osteoporosis to guide treatment. PMC
3. Echocardiography. Screens the aortic root and heart for complications associated with connective-tissue weakness. NCBI
4. MR angiography or CT angiography of head/neck/chest/abdomen (with Doppler ultrasound where appropriate). Finds aneurysms, dissections, or vessel tortuosity early to prevent rupture. NCBI

Non-pharmacological treatments (therapies & other measures)

1. Fracture-prevention lifestyle plan
   Description: Teach safe movement, fall-proof the home, and use supportive footwear and hip protectors. Avoid high-impact athletics and sudden twisting. Encourage gentle, regular weight-bearing activity as tolerated. Purpose: Fewer fractures and better day-to-day function. Mechanism: Lower fall energy + better balance decreases bone stress; small, frequent loading signals bone to maintain strength. NCBI

2. Physiotherapy for contractures
   Description: Daily, gentle stretching, serial casting, splinting, and task-oriented therapy. Start early; tailor to each joint. Include caregiver training. Purpose: Improve range, alignment, and function; delay surgery. Mechanism: Slow tissue lengthening and joint alignment reduce stiffness; repetitive practice strengthens muscles around fragile joints. MSD Manuals+1

3. Assistive devices & bracing
   Description: Custom ankle-foot orthoses, knee-ankle-foot braces, wrist/hand splints, walkers, or wheelchairs; ergonomic home and school/work setups. Purpose: Safer mobility, joint protection, energy conservation. Mechanism: External support redistributes force away from weak bone and tight joints to reduce injury risk. jposna.com

4. Bone-safe physical activity
   Description: Guided, low-impact programs: aquatic therapy, supported treadmill or recumbent cycle, isometrics, and posture/core routines. Purpose: Build muscle and balance without overload. Mechanism: Muscle pull stimulates bone and stabilizes joints; water buoyancy reduces impact. NCBI

5. Hearing rehabilitation
   Description: Early audiology referral; fit hearing aids or bone-anchored hearing systems; consider cochlear implant if severe sensorineural loss. Provide speech-language therapy and classroom support. Purpose: Preserve communication, education, and quality of life. Mechanism: Devices amplify or bypass damaged pathways; early input prevents language delay. Nature+1

6. Arterial risk surveillance
   Description: Baseline and periodic vascular imaging (e.g., ultrasound/MRA/CTA) to check for aneurysm/dissection; emergency plans for sudden pain. Educate on symptoms. Purpose: Detect problems early and treat fast. Mechanism: Surveillance finds weak vessel segments before rupture; rapid response reduces fatality. NCBI

7. Blood pressure optimization (non-drug)
   Description: Salt moderation, weight control, sleep hygiene, stress reduction, and regular gentle activity; home BP monitoring. Purpose: Keep arterial wall stress low. Mechanism: Lower systolic BP reduces peak mechanical load on fragile arteries. NCBI

8. Vision care
   Description: Annual ophthalmology for myopia, cataract, vitreoretinal issues; prompt care for flashes/floaters. Protective eyewear for sports. Purpose: Prevent retinal detachment and vision loss. Mechanism: Early detection and protection minimize traction and impact on fragile ocular tissues. NCBI

9. Pain self-management skills
   Description: Heat/cold, relaxation, paced activity, CBT-style coping strategies; ergonomics training. Purpose: Lower daily pain and medication reliance. Mechanism: Central and peripheral pain modulation; reduced muscle guarding lessens joint load. NCBI

10. Nutrition for bone and vessel health
    Description: Adequate calcium, vitamin D, protein; emphasize fruits/vegetables, omega-3 fish; limit ultra-processed foods and added salt. Purpose: Support bone mineralization and vascular health. Mechanism: Calcium/Vitamin D enable mineral deposition; protein provides collagen building blocks; omega-3s support endothelial function. Office of Dietary Supplements+2Office of Dietary Supplements+2

11. Falls prevention program
    Description: Home safety audit (lighting, rails, non-slip mats), footwear review, and balance training. Purpose: Reduce fracture-causing falls. Mechanism: Environmental control + balance improve stability and reduce trip hazards. NCBI

12. Fracture-care pathway
    Description: Written plan for immobilization choices, safe transfers, pressure-relief cushions, and DVT prevention during casting. Purpose: Consistent, safer fracture management. Mechanism: Standardization lowers complication risk in fragile bone. NCBI

13. Respiratory and spine monitoring
    Description: Track scoliosis/kyphosis; consider bracing; pulmonary function checks if restrictive pattern suspected. Purpose: Maintain breathing capacity and posture. Mechanism: Early orthotic or surgical referral prevents late collapse. NCBI

14. Dental care and jaw protection
    Description: Regular dental checks; avoid traumatic extractions when possible; discuss nitrous sedation vs regional blocks carefully. Purpose: Prevent jaw fractures and dental complications. Mechanism: Gentle technique and preventive care reduce bone stress. NCBI

15. Genetic counseling & family planning
    Description: Explain autosomal-recessive inheritance; discuss carrier testing and options. Purpose: Informed reproductive decisions. Mechanism: Identifying PLOD3 variants clarifies recurrence risk. NCBI

16. School/work accommodations
    Description: Seating, ergonomic tools, flexible PE, lift assistance, and evacuation plans. Purpose: Safe inclusion and productivity. Mechanism: Reduces repetitive mechanical load and injury risk. jposna.com

17. Emergency “passport”
    Description: Wallet card with diagnosis, vascular risk, safe handling tips, and treating-team contacts. Purpose: Faster, safer emergency decisions. Mechanism: Reduces harmful procedures (e.g., excessive manipulation) and speeds imaging/surgery when needed. NCBI

18. Psychosocial support
    Description: Counseling, peer groups, and caregiver support services. Purpose: Reduce anxiety/depression; improve adherence. Mechanism: Better coping lowers stress physiology and improves self-care. NCBI

19. Peri-procedural planning
    Description: For anesthesia, intubation, positioning, and tourniquet use, adopt gentle techniques and extra padding; consider vascular risk in any invasive plan. Purpose: Prevent iatrogenic injury. Mechanism: Minimizes shear/pressure on fragile tissues and vessels. NCBI

20. Vaccination & infection prevention
    Description: Routine immunizations, flu shots, and prompt infection care to avoid coughing falls and post-infectious deconditioning. Purpose: Maintain strength and reduce fracture-provoking events. Mechanism: Fewer systemic stressors = steadier bone/muscle status. NCBI

---

Drug treatments

Important: No medicines are FDA-approved specifically for BCARD. Drugs below are used to manage bone fragility, pain, and blood-pressure/vascular risk, extrapolating from osteoporosis/OI or cardiovascular care. Doses are examples from FDA labels for their approved uses—clinicians tailor dosing to the person and indication.

1. Zoledronic acid (Reclast®/Zoledronic Acid Injection) — IV bisphosphonate
   Class: Antiresorptive. Typical dose (osteoporosis): 5 mg IV once yearly. Time: Yearly infusion. Purpose: Increase BMD and reduce fractures. Mechanism: Inhibits osteoclasts → less bone breakdown; net bone strength improves. Side effects: Flu-like reaction, hypocalcemia, renal issues; rare osteonecrosis of the jaw/atypical femur fracture. FDA Access Data+1

2. Pamidronate (Aredia®/Pamidronate Disodium) — IV bisphosphonate
   Class: Antiresorptive. Typical dose (Paget’s template/oncology varies): Intermittent IV courses. Purpose: Strengthen bone and reduce fracture pain; widely used off-label in pediatric OI. Mechanism: Osteoclast inhibition. Side effects: Flu-like symptoms, hypocalcemia, infusion-site issues; renal cautions. FDA Access Data+1

3. Denosumab (Prolia®) — SC monoclonal antibody against RANKL
   Class: Antiresorptive. Dose (osteoporosis): 60 mg SC every 6 months with calcium/vitamin D. Purpose: Boost BMD, reduce fractures. Mechanism: Blocks osteoclast formation/function. Side effects: Hypocalcemia (notably in CKD), infections, dermatologic reactions; jaw osteonecrosis risk. Rebound bone loss if stopped abruptly. FDA Access Data+1

4. Teriparatide (Forteo®/Teriparatide Injection/Bonsity®) — SC PTH(1-34) analog
   Class: Anabolic bone agent. Dose: 20 mcg SC daily (limited duration per label). Purpose: Build bone in severe osteoporosis (adults). Mechanism: Intermittent PTH stimulates osteoblasts > osteoclasts. Side effects: Transient hypercalcemia, dizziness, leg cramps; historical osteosarcoma warning revised—see label. Not for children with open growth plates. FDA Access Data+2FDA Access Data+2

5. Abaloparatide (Tymlos®) — SC PTHrP analog
   Class: Anabolic. Dose: 80 mcg SC daily (label duration limits). Purpose: Alternative anabolic therapy in high-risk adult osteoporosis. Mechanism: Activates PTH1 receptor to promote bone formation. Side effects: Hypercalciuria, dizziness, orthostasis; osteosarcoma risk language; supplement calcium/vitamin D if needed. FDA Access Data+1

6. Romosozumab (Evenity®) — SC anti-sclerostin antibody
   Class: Anabolic + antiresorptive effects. Dose: 210 mg SC monthly for 12 months. Purpose: Rapid BMD gains in severe osteoporosis (postmenopausal adults). Mechanism: Increases bone formation and decreases resorption. Side effects: Injection reactions; boxed warning for MI/stroke—avoid in recent cardiovascular events. FDA Access Data

7. Vitamin D3 (cholecalciferol) — supplement (adjunct to any bone drug)
   Class: Vitamin. Dose: Individualized to reach sufficient 25-OH-D; common maintenance 600–2000 IU/day in adults. Purpose: Support mineralization and prevent antiresorptive-induced hypocalcemia. Mechanism: Increases calcium absorption. Side effects: Excess can cause hypercalcemia. (Evidence basis from NIH ODS.) Office of Dietary Supplements

8. Calcium (citrate/carbonate) — supplement
   Class: Mineral. Dose: Typically 1000–1200 mg/day dietary + supplement to meet target; split doses. Purpose: Provide building block for bone; necessary with antiresorptives. Mechanism: Substrate for hydroxyapatite. Side effects: Constipation, kidney stone risk in excess. (NIH ODS.) Office of Dietary Supplements

9. Ibuprofen (various labels, incl. Advil®/Motrin®) — analgesic/NSAID
   Class: NSAID. Dose (OTC adult): 200 mg q4–6h PRN; max per label. Purpose: Fracture and post-cast pain relief (short term). Mechanism: COX inhibition reduces prostaglandins (pain/inflammation). Side effects: GI upset/bleeding, renal risk—use lowest effective dose, shortest time. FDA Access Data+1

10. Acetaminophen (paracetamol) — analgesic/antipyretic
    Class: Non-opioid analgesic. Dose (typical adult max): Up to 3–4 g/day considering all sources. Purpose: Baseline pain control, opioid-sparing. Mechanism: Central analgesia. Side effects: Liver toxicity in overdose or with alcohol. FDA Access Data+1

11. Losartan (Cozaar®/combinations) — ARB antihypertensive
    Class: Angiotensin II receptor blocker. Dose (HTN): Often 50 mg daily, titrate. Purpose: Lower arterial wall stress to reduce rupture risk. Mechanism: Blocks angiotensin II vasoconstriction; lowers BP. Side effects: Dizziness, hyperkalemia, renal effects. FDA Access Data+1

12. Amlodipine (Norvasc®; solutions like Norliqva®) — calcium-channel blocker
    Class: Dihydropyridine CCB. Dose (HTN): 5–10 mg daily (adult). Purpose: BP control if ARB not tolerated/insufficient. Mechanism: Vasodilation → lower pressure. Side effects: Edema, flushing, headache. FDA Access Data+1

13. Labetalol (oral/IV forms) — beta-/alpha-blocker
    Class: Antihypertensive. Dose: Individualized; used orally for chronic control or IV acutely. Purpose: BP control, especially periprocedurally. Mechanism: Blocks adrenergic tone → reduce heart rate and vascular resistance. Side effects: Hypotension, bradycardia, fatigue. FDA Access Data+1

14. Propranolol (Inderal®; extended-release variants) — beta-blocker
    Class: Beta-blocker. Dose: Varies by formulation/indication. Purpose: Additional BP/HR control when appropriate. Mechanism: Lowers sympathetic drive. Side effects: Bradycardia, bronchospasm, fatigue; taper slowly to avoid rebound. FDA Access Data

15. Combination acetaminophen/ibuprofen (e.g., Combogesic®) — fixed-dose
    Class: Non-opioid analgesic combo. Dose: As per label. Purpose: Better pain relief while minimizing opioids. Mechanism: Peripheral COX inhibition + central analgesia. Side effects: NSAID + acetaminophen risks combined—respect both maxima. FDA Access Data

16. Short-term opioid analgesics (e.g., hydrocodone/acetaminophen) — rescue only
    Class: Opioid combination. Dose: As per label; smallest effective amount. Purpose: Severe acute pain after major fractures/surgery when non-opioids insufficient. Mechanism: µ-opioid receptor agonism. Side effects: Sedation, constipation, dependence—use sparingly. FDA Access Data

17. Zoledronic acid (oncology formulations) — alternative label reference
    Note: Same active ingredient as Reclast but different dosing for oncology. Purpose/Mechanism/risks: As in #1; label distinctions matter clinically. FDA Access Data

18. Teriparatide (biosimilar/alternate labeling: Bonsity®) — reference
    Purpose/Mechanism/risks: As in #4; label cautions about calcium and digoxin. FDA Access Data

19. Topical analgesics (adjuncts) — (capsaicin, diclofenac gel)
    Purpose: Local pain relief with less systemic exposure. Mechanism: Local nociceptor desensitization/COX inhibition. Side effects: Skin irritation. (Use product-specific FDA labels.) FDA Access Data

20. Peri-fracture DVT prophylaxis when immobilized — heparins (context-specific)
    Purpose: Prevent clots during casting/limited mobility. Mechanism: Anticoagulation. Side effects: Bleeding risk; must be individualized, especially with arterial fragility. (Use specific FDA label per agent; specialist-led.) NCBI

---

Dietary molecular supplements

1. Vitamin D3 — Typical maintenance 600–2000 IU/day; titrate to sufficiency. Function: Calcium absorption, bone mineralization. Mechanism: Upregulates transport proteins and bone remodeling signals. Caution: Avoid excess (hypercalcemia). Office of Dietary Supplements

2. Calcium (diet first, then supplement) — 1000–1200 mg/day total intake. Function: Bone matrix mineral. Mechanism: Provides hydroxyapatite substrate. Caution: Kidney stone risk if excessive; split doses. Office of Dietary Supplements

3. Protein (whey/food-based) — ~1.0–1.2 g/kg/day unless restricted. Function: Collagen and muscle synthesis. Mechanism: Amino acids (lysine/proline) support collagen cross-linking and strength. Caution: Adjust for renal status. Office of Dietary Supplements

4. Vitamin K (K1/K2) — Dietary sources (greens) ± supplement if low intake. Function: γ-carboxylation of osteocalcin (bone quality) and coagulation proteins. Mechanism: Enables calcium binding in bone matrix. Caution: Drug interactions (warfarin). Office of Dietary Supplements

5. Magnesium — RDA-based supplementation if dietary intake low. Function: Bone matrix and vitamin D metabolism. Mechanism: Cofactor in bone mineralization. Caution: Diarrhea with excess; adjust in CKD. Office of Dietary Supplements

6. Omega-3 fatty acids (EPA/DHA) — Fish 2x/week or supplements per ODS guidance. Function: Cardiovascular support and inflammation modulation. Mechanism: Membrane effects, eicosanoid balance; may aid endothelial function. Caution: Bleeding risk at high doses. Office of Dietary Supplements

7. Vitamin C (food-first) — Supports collagen hydroxylation. Mechanism: Cofactor for prolyl/lysyl hydroxylases in collagen. Caution: Kidney stone risk at very high doses. Office of Dietary Supplements

8. Phosphate and trace minerals (balanced diet) — Zinc, copper, manganese for collagen enzymes. Mechanism: Enzymatic cofactors in matrix formation. Caution: Avoid megadoses; balance matters. Office of Dietary Supplements

9. L-lysine (dietary amino acid) — Collagen building block; prioritize protein-rich foods. Mechanism: Substrate for cross-linking. Caution: Supplement only if intake is inadequate. Office of Dietary Supplements

10. Folate/B-complex (if deficient) — Supports cell turnover and homocysteine control (bone risk marker). Caution: Test-and-treat approach. Office of Dietary Supplements

---

Immunity-booster / regenerative / stem-cell–related drugs

1. Romosozumab (Evenity®) — Regenerative-leaning anabolic for osteoporosis; not for children; avoid with recent MI/stroke. Dose: 210 mg monthly for 12 months. Mechanism: Anti-sclerostin → ↑formation, ↓resorption. FDA Access Data

2. Teriparatide (Forteo®) — Anabolic bone formation agent; adults only; time-limited use. Mechanism: Intermittent PTH stimulates osteoblasts. FDA Access Data

3. Abaloparatide (Tymlos®) — Anabolic alternative to teriparatide (adults). FDA Access Data

4. Denosumab (Prolia®) — Potent antiresorptive that can indirectly allow net bone “rebuilding” with careful calcium/vitamin D support; rebound on stop. FDA Access Data

5. Investigational mesenchymal stem-cell therapies — Experimental in brittle-bone disorders; not FDA-approved for BCARD/OI; consider only in clinical trials. Mechanism: Proposed matrix support/regeneration. (General caution aligned with lack of FDA approval.) NCBI

6. Comprehensive vaccination (immune resilience) — Not a “drug” for bone, but key to reduce illness-related deconditioning and fall risk; follow national schedules. NCBI

---

Surgeries

1. Corrective osteotomy with internal fixation — Re-aligns deformed, fracture-prone long bones; improves load distribution and function. Why: Reduce pain, prevent new fractures, enable bracing/mobility. Note: Gentle handling due to fragile bone. NCBI

2. Spinal fusion for scoliosis/kyphosis (select cases) — Stabilizes severe curves affecting function or breathing. Why: Prevent progression and restrictive lung issues; improve sitting/standing alignment. NCBI

3. Vascular repair (open or endovascular) — Treats detected aneurysm/dissection to prevent rupture; choice depends on anatomy and tissue fragility. Why: Life-saving intervention. NCBI

4. Orthopedic soft-tissue release for contractures — Tendon lengthening or capsular release when conservative care fails. Why: Improve range, hygiene, bracing fit, and sitting/standing function. MSD Manuals

5. Cochlear implantation / ossicular procedures — For severe hearing loss not helped by aids; stapes surgery has variable success in OI-like ears, while implants can restore speech perception in selected cases. Why: Communication and quality-of-life gains. Nature

---

Preventions

1. Keep BP in target and check at home. NCBI

2. Use braces/orthoses consistently during risky activities. jposna.com

3. Vitamin D + calcium sufficiency; prioritize diet + safe sun. Office of Dietary Supplements+1

4. Fall-proof your home; practice balance drills. NCBI

5. Early audiology checks; treat hearing decline promptly. ASHA Apps

6. Annual ophthalmology if ocular risks. NCBI

7. Emergency plan for sudden chest/abdominal/back pain. NCBI

8. Avoid tobacco; limit alcohol—bone and vessel friendly. Office of Dietary Supplements

9. Gentle, regular exercise; avoid high-impact sports. NCBI

10. Keep vaccinations up to date to reduce illness-triggered setbacks. NCBI

---

When to see doctors

• Emergency now for sudden, severe chest/neck/abdominal/back pain, fainting, stroke signs, or a “tearing” sensation—possible arterial dissection/rupture. NCBI

• Urgent if a new fracture, uncontrolled pain, numb/blue limb after casting, or sudden new hearing/vision loss. NCBI+1

• Soon for rising home BP readings, new swelling, or medication side effects (e.g., jaw pain/swelling while on antiresorptives; muscle cramps or tingling with denosumab). FDA Access Data

• Routine: 6–12-monthly bone/vascular/hearing/vision follow-ups; earlier in growth spurts or after major events. NCBI+1

---

What to eat and what to avoid

1. Eat: Dairy/fortified alternatives, small fish with bones, leafy greens, beans, nuts—calcium-rich. Avoid: Persistently low-calcium patterns. Office of Dietary Supplements

2. Eat: Protein with every meal (eggs, dairy, legumes, fish, lean meats). Avoid: Very low-protein diets. Office of Dietary Supplements

3. Eat: Vitamin-D sources (fortified foods, oily fish) + supplement as advised. Avoid: Long-term deficiency. Office of Dietary Supplements

4. Eat: Greens for vitamin K (spinach, kale). Avoid: Large, erratic K swings if on warfarin—aim for steady intake. Office of Dietary Supplements

5. Eat: Omega-3 fish (salmon, sardines) weekly. Avoid: Excess trans fats/ultra-processed snacks. Office of Dietary Supplements

6. Drink: Plenty of water. Avoid: Sugary drinks; excess alcohol (bone harm, falls). Office of Dietary Supplements

7. Balance: Fruits/vegetables (potassium, magnesium). Avoid: Chronic high-salt intake (BP rises). Office of Dietary Supplements

8. Consider: Vitamin C-rich foods for collagen enzymes. Avoid: Mega-supplement dosing without need. Office of Dietary Supplements

9. If on antiresorptives: Take calcium/Vit-D consistently as directed. Avoid: Skipping supplements (hypocalcemia risk with denosumab). FDA Access Data

10. If reflux/ulcer risk: Favor food-first pain control and discuss NSAID use. Avoid: Long NSAID courses without GI protection. FDA Access Data

---

FAQs

1) Is BCARD the same as osteogenesis imperfecta?
No. BCARD is distinct and linked to PLOD3/LH3 deficiency in reports, but it overlaps with OI in bone fragility and hearing issues. Many care strategies borrow from OI because high-quality BCARD trials don’t exist yet. NCBI

2) Why do arteries rupture?
Collagen in vessel walls is weaker, so pressure and shear can cause aneurysm or dissection. Keeping blood pressure controlled and monitoring vessels lowers risk. NCBI

3) Can bones actually get stronger?
Yes—antiresorptives and anabolic agents can improve bone density and reduce fractures in related conditions; combine with nutrition and safe exercise. Individual response varies. FDA Access Data+1

4) Will hearing always worsen?
Not always. Hearing loss patterns vary. Early testing lets you adopt hearing aids, bone-anchored devices, or cochlear implants when appropriate. Nature

5) Is stapes surgery a good idea?
It can help in selected patients but success in OI-like ears is variable, and revision risk exists; implantable options may be more reliable in some cases. Nature

6) Are these bone drugs approved for BCARD?
No. They’re used off-label to treat bone fragility extrapolating from osteoporosis/OI evidence. Discuss risks and benefits with specialists. FDA Access Data+1

7) Can children use the same medicines as adults?
Some (e.g., pamidronate) are widely used off-label in pediatric OI centers; teriparatide/abaloparatide/romosozumab are adult-only per labels. FDA Access Data+3FDA Access Data+3FDA Access Data+3

8) Do I need surgery for contractures?
Often, no—early therapy, splints, and serial casting help. Surgery is reserved for severe, function-limiting cases after conservative care. MSD Manuals

9) How often should arteries be imaged?
Your team will individualize based on baseline findings and symptoms. Many vEDS-style programs use periodic non-invasive imaging plus strict emergency plans. NCBI

10) What about pregnancy?
Pregnancy can strain vessels. High-risk obstetrics plus vascular/cardiology input is essential; plan delivery in a tertiary center. NCBI

11) Will glasses help my eye risks?
Glasses correct myopia, but you still need retina checks because detachment risk comes from tissue fragility, not just refraction. NCBI

12) Which pain medicine is “safest”?
Start with acetaminophen; short NSAID courses may help; reserve opioids for severe acute pain and short durations. Always consider GI/renal/bleeding risks. FDA Access Data+1

13) Do supplements replace medicines?
No. Vitamin D and calcium support bone drugs; alone, they rarely fix severe fragility. Food-first plus targeted supplements is best. Office of Dietary Supplements+1

14) Can exercise be harmful?
High-impact moves can be; guided, low-impact programs are usually helpful. Work with therapists to personalize. NCBI

15) Is there a cure?
Not yet. Treatment focuses on risk reduction, surveillance, and function. Research in collagen biology and bone anabolics continues. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.